Where Will Tumor-Infiltrating Lymphocyte (TIL) Therapy Fit Into the Oncologic Landscape?

In the first installment of the series, Allison Betof Warner, MD, PhD, reviews the mechanistic rationale behind tumor-infiltrating lymphocytes and considers where these experimental therapies may fit in the oncologic landscape.

Related Videos
Expert on NSCLC
Expert on NSCLC
Expert on NSCLC
Experts on NSCLC
Expert on NSCLC
Expert on NSCLC
Related Content